STE — STERIS plc

Summary of STERIS plc Q4 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Grew 7% year-over-year; constant currency organic revenue increased by 5%.
• Gross Margin: 44%, down 30 basis points from the prior year.
• EBIT Margin: 24.2%, a high for fiscal 2026 but 60 basis points lower than Q4 2025, impacted by inflation and tariffs.
• Adjusted Net Income: $278.3 million; earnings per diluted share at $2.83, a 3% increase over the previous year.
• Effective Tax Rate: Adjusted effective tax rate increased to 25.4% from 23.5% year-over-year.
• Free Cash Flow: Exceptional at $982.9 million, driven by increased earnings.
• Capital Expenditures: Totaled $369 million; depreciation and amortization at $486.5 million.
• Debt: Total debt at $1.9 billion with a gross debt to EBITDA ratio of approximately 1.2x.

2. Strategic Updates and Business Highlights

• Record Year: Fiscal 2026 marked a record year with total revenue around $6 billion and adjusted net income exceeding $1 billion.
• Segment Performance:
  • Healthcare: Grew 9% as reported; services grew 12%.
  • AST: Grew 10% as reported; services grew 11%.
  • Life Sciences: Grew 9% as reported, driven by 15% growth in capital equipment.
• M&A Activity: Completed two tuck-in acquisitions in Healthcare, expected to contribute approximately $45 million in revenue for fiscal 2027.
• Share Buyback: Board approved a new $1 billion buyback authorization, with plans to repurchase $200 million to $300 million annually.

3. Forward Guidance and Outlook

• Fiscal 2027 Revenue Growth: Anticipated to grow 7% to 8% as reported; constant currency organic growth expected at 6% to 7%.
• Earnings Per Share: Projected between $11.10 and $11.30, representing a growth of 9% to 11% over fiscal 2026.
• EBIT Margin Expansion: Expected to expand approximately 50 basis points.
• Free Cash Flow: Expected to be $850 million with capital expenditures of $375 million.
• Investment Plans: Plans to build a new sterility assurance manufacturing plant in Mentor, Ohio, with a $60 million investment over two years.

4. Bad News, Challenges, or Points of Concern

• Tariff Impact: Incremental tariffs impacted the fourth quarter by approximately $10 million; total tariff costs for fiscal 2026 were around $60 million to $65 million, with no refunds assumed for fiscal 2027.
• AST Segment Challenges: Noted softness in AST services, particularly in Q4 due to severe weather and inventory management by customers.
• Tax Rate Pressure: Anticipated increase in the effective tax rate due to capital allocation priorities and withholding taxes.
• Inventory Management: Med tech customers are managing inventory levels carefully, potentially impacting demand in the short term.

5. Notable Q&A Insights

• Margin Guidance: Management discussed operational improvements and higher-margin product sales as key drivers for margin expansion.
• USMCA Review: No assumptions included in guidance regarding the USMCA renegotiation, which is expected to continue without significant changes.
• Supply Chain Resilience: Management expressed confidence in supply chain improvements and mitigation strategies for critical components, including chips.
• Life Sciences Outlook: Positive sentiment regarding growth in Life Sciences driven by reshoring and capital investment, although smaller players are lagging.
• AST Volume Recovery: Management expects a slow start in the first half of fiscal 2027 for AST but anticipates recovery as procedure volumes increase.

This summary captures the essential elements of STERIS plc's Q4 2026 earnings call, providing a balanced view of their financial performance, strategic initiatives, and outlook while highlighting potential challenges.